SYSTM Wealth Solutions LLC Sells 149 Shares of Eli Lilly and Company (NYSE:LLY)

SYSTM Wealth Solutions LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 7.2% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 1,929 shares of the company’s stock after selling 149 shares during the period. SYSTM Wealth Solutions LLC’s holdings in Eli Lilly and Company were worth $1,747,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. E Fund Management Co. Ltd. increased its position in shares of Eli Lilly and Company by 0.9% during the 2nd quarter. E Fund Management Co. Ltd. now owns 5,211 shares of the company’s stock valued at $4,718,000 after purchasing an additional 46 shares during the last quarter. Bradley Foster & Sargent Inc. CT increased its position in shares of Eli Lilly and Company by 2.8% during the 2nd quarter. Bradley Foster & Sargent Inc. CT now owns 20,181 shares of the company’s stock valued at $18,272,000 after purchasing an additional 558 shares during the last quarter. L & S Advisors Inc increased its position in shares of Eli Lilly and Company by 5.1% during the 2nd quarter. L & S Advisors Inc now owns 19,116 shares of the company’s stock valued at $17,307,000 after purchasing an additional 934 shares during the last quarter. Fairway Wealth LLC purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at about $65,000. Finally, Abbot Financial Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at about $206,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Bank of America upped their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and increased their target price for the stock from $725.00 to $1,025.00 in a report on Monday, August 12th. Berenberg Bank increased their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Finally, Barclays increased their target price on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $977.35.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the transaction, the insider now directly owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders sold 451,900 shares of company stock worth $418,732,178. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Trading Down 1.9 %

Shares of LLY opened at $906.17 on Wednesday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a 1 year low of $516.57 and a 1 year high of $972.53. The company has a 50 day simple moving average of $896.70 and a two-hundred day simple moving average of $835.96. The firm has a market cap of $861.23 billion, a P/E ratio of 133.46, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. On average, equities analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.57%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.